vimarsana.com

Page 2 - Research Report Initial Coverage News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Original-Research: publity AG (von GBC AG): BUY

Original-Research: publity AG - von GBC AG Einstufung von GBC AG zu publity AG Unternehmen: publity AG ISIN: DE0006972508 Anlass der Studie: Research Report (Initial Coverage) Empfehlung: BUY

United statesMarcel schafferMatthias greiffenbergerResearch report initial coverageGlobal ofce real estate technologyResearch reportInitial coverageOfce real estateAnnual general meetingEinen katalog

Original-Research: Advanced Blockchain AG (von GBC AG): BUY

Original-Research: Advanced Blockchain AG - von GBC AG Einstufung von GBC AG zu Advanced Blockchain AG Unternehmen: Advanced Blockchain AG ISIN: DE000A0M93V6 Anlass der Studie: Research Report

Julien desrosiersFelix hauggMatthias greiffenbergerResearch report initial coverageAdvanced blockchainResearch reportInitial coverageComposable financeEinen katalog

Original-Research: EAMD European AeroMarine Drones AG (von GBC AG): BUY

Original-Research: EAMD European AeroMarine Drones AG - von GBC AG Einstufung von GBC AG zu EAMD European AeroMarine Drones AG Unternehmen: EAMD European AeroMarine Drones AG ISIN: DE0006611957

Marcel schafferMatthias greiffenbergerResearch report initial coverageAeromarine dronesResearch reportInitial coverageReiner stemme aero gmbhReiner stemme red eagleRed eagleEinen katalogGerman versionEnglish version

Original-Research: Defence Therapeutics Inc (von GBC AG): BUY

^ Original-Research: Defence Therapeutics Inc. - von GBC AG Einstufung von GBC AG zu Defence Therapeutics Inc. Unternehmen: Defence Therapeutics Inc. ISIN: CA24463V1013 Anlass der Studie: Research Report (Initial Coverage) Empfehlung: BUY Kursziel: 11,02 CAD (7,06 EUR) Kursziel auf Sicht von: 31.

Julien desrosiersCosmin filkerDefence therapeutics incResearch report initial coverageDefence therapeuticsResearch reportInitial coverageCancer vaccinesEinen katalog

Original-Research: Defence Therapeutics Inc (von GBC AG): BUY

Original-Research: Defence Therapeutics Inc. - von GBC AG Einstufung von GBC AG zu Defence Therapeutics Inc. Unternehmen: Defence Therapeutics Inc. ISIN: CA24463V1013 Anlass der Studie: Research

Julien desrosiersCosmin filkerDefence therapeutics incResearch report initial coverageDefence therapeuticsResearch reportInitial coverageCancer vaccinesEinen katalog

vimarsana © 2020. All Rights Reserved.